Considering that the depletion of tumor infiltrating FoxP3+ Tregs by anti-CD25 monotherapy resulted in only partial tumor control and large-dose possible complications [11], it was necessary to identify further interventions to increase clinical efficacy and tumor specific immune response. This evidence concerns the gene FOXP3 and neoplasm.